OncoMatch/Clinical Trials/NCT06754267
Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL
Is NCT06754267 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Venetoclax and Olverembatinib for precursor b-cell acute lymphoblastic leukemia.
Treatment: Venetoclax · Olverembatinib · Predinisone — Precursor B cell acute lymphoblastic leukemia (B-ALL) is an aggressive type of leukemia, with high relapse rate and poor long term survival in adults. Philadelphia chromosome positive (Ph+) ALL is defined as ALL with translocation between chromosomes 9 and 22. And t(9;22)(q34;q11) is the most common chromosomal abnormality in ALL. Before the emergence of TKI, the prognosis of Ph+ ALL was extremely poor, and the long-term survival rate was only 10%-35%. Ph+ ALL accounts for about 30% of adult ALL. In this study, the investigators propose a treatment approach that combines Venetoclax with Olverembatinib and Predinisone in Ph+ B-ALL adults. The study aims to answer the safety and efficacy of this treatment regimen, and further improve the survival for those participants.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: BCR fusion
positive for Philadelphia chromosome (presence of t(9;22) and/or BCR::ABL1 positive and/or FISH positive)
Required: ABL1 fusion
positive for Philadelphia chromosome (presence of t(9;22) and/or BCR::ABL1 positive and/or FISH positive)
Disease stage
Excluded: Stage ACCELERATED PHASE OR BLAST CRISIS OF CHRONIC MYELOID LEUKEMIA
Accelerated phase or blast crisis of chronic myeloid leukemia [excluded]
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: systemic anti-leukemia treatment
Exception: allowed pretreatment
Subjects who have received systemic anti-leukemia treatment (including but not limited to TKI, radiotherapy or chemotherapy, except for the allowed pretreatment)
Lab requirements
Kidney function
serum creatinine > 1.5 uln
Liver function
serum total bilirubin > 1.5 uln; alt or ast > 2.5 uln
Cardiac function
left ventricular ejection fraction (lvef) on echocardiography <50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06754267 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require BCR?
Yes, BCR fusion is a required biomarker for enrollment.
Does this trial require ABL1?
Yes, ABL1 fusion is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify